| Literature DB >> 28959575 |
Dulciana S do Monte1, Jonh A Bezerra Tenório1, Isla V G A Bastos2, Fábio de S Mendonça3, Joaquim E Neto3, Teresinha G da Silva2, Clécio S Ramos1.
Abstract
Considering the increase in consumption of Cannabis sativa and the use of the compound β-carotene (BC) as supplement, we investigated potential changes in the chemical and biological proprieties of BC after exposure to C. sativa smoke (CSS). Our results showed that the BC exposed to CSS underwent 98.8% degradation and suffered loss of its antiradical activity. The major degradation products identified were 3-hydroxy-2,4,4-trimethylpentyl)2-methylpropanoate and (2-ethyl-3-hydroxyhexyl)2-methylpropanoate compounds. These are found in higher levels in the exhalations of colorectal cancer patients and are similar to the toxic products associated with lipid peroxidation of polyunsaturated fatty acids. In toxicological assays using micro-crustacean Artemia salina the BC was non-toxic, while the BC degraded by CSS had a toxicity of LC50 = 397.35 μg/mL. In Wistar rats, females treated with BC degraded by CSS (BCCSS) showed whitish liver spots, alterations in liver weight and in bilirubin and alkaline phosphatase levels, and decrease in the number of leukocytes associated with atypical lymphocytosis. In male rats, there was an increase in the number of leukocytes when compared to the control group. In the histopathological analysis, the cortical region of the kidneys showed the presence of discrete amorphous eosinophilic material (cylinders) in the lumen of the proximate and distal convoluted tubules. In general, the BC in contact with CSS undergoes chemical changes and exhibits toxicity to rats and Artemia salina.Entities:
Keywords: Cannabis sativa smoke; Degradation; Toxicity; β-Carotene
Year: 2016 PMID: 28959575 PMCID: PMC5615942 DOI: 10.1016/j.toxrep.2016.06.001
Source DB: PubMed Journal: Toxicol Rep ISSN: 2214-7500
Fig. 1UV–vis spectra of β-carotene after exposed to C. sativa smoke.
Identified compounds by GC–MS after β-carotene exposed to C. sativa smoke.
| N° | Compound | Molecular formula | RT min | % | Main fragments ( |
|---|---|---|---|---|---|
| 1 | (3-Hydroxy−2,4,4-trimethylpentyl)2-methylpropanoate | C12H24O3 | 19.5 | 30.0 | 43, 56, 71, 83, 98 |
| 2 | (2-ethyl−3-hydroxyhexyl)2-methylpropanoate | C12H24O3 | 20.5 | 20.1 | 43, 56, 71, 89, 173 |
| 3 | dihydroactinidiolide | C11H16O2 | 26.2 | 3.0 | 43, 111, 137, 180 |
| C10H16O | 32.6 | 3.7 | 69, 109, 137, 152 | ||
| 4 | Cannabidiol | C21H30O2 | 47.9 | 0.3 | 55, 147, 231, 267 |
| 5 | 2-tridecen−1-al | C13H24O | 49.2 | 1.0 | 43, 149, 167, 231 |
| 6 | Ergost-5-en-3-ol, acetate, (3 | C30H50O2 | 49.5 | 0.4 | 43, 55, 231, 367 |
| 7 | Δ9-tetrahydrocannabinol | C21H30O2 | 50.3 | 11.4 | 258, 271, 299, 314 |
| 8 | Cannabigerol | C21H32O2 | 51.2 | 1.0 | 43, 55, 69, 123, 193, 231, 295 |
| 9 | Cannabinol | C21H26O2 | 51.6 | 5.4 | 119, 238, 295, 310 |
| 10 | Hexadecane,6, 11-dipentyl | C26H54 | 53.3 | 1.1 | 43,71, 85, 295, 313 |
| 11 | Farnesol isomer A | C15H26O | 53.7 | 3.2 | 55, 69, 81, 95, 295 |
| 12 | Hexatriacontane | C36H74 | 55.1 | 0.9 | 43, 57, 71, 85, 99 |
| 13 | Tetracosane, 9-octyl- | C32H66 | 56.3 | 0.2 | 43, 57, 71, 85 |
| TOTAL | – | – | 81.7 | – |
Probable degradation products of BC after exposure to CSS.
Fig. 2Graphical plot of effective concentration values (EC50) of ABTS radical scavenging activities of the samples of BC, BCCSS and CSS.
Values of water and food consumption, variation in body and organ weight of male and female rats after exposure to BC, CSS and BCCSS for 30 days.
| Groups | Animals | Water | Food | Body | Lung | Heart | Liver | Kidney (g) | Spleen (g) | Stomach |
|---|---|---|---|---|---|---|---|---|---|---|
| Negative control | Male | 181.1 ± 29.9 | 156.4 ± 14.9 | 320.4 ± 3.7 | 1.96 ± 0.23 | 1.23 ± 0.07 | 12.27 ± 0.95 | 2.49 ± 0.14 | 1.02 ± 0.15 | 1.72 ± 0.06 |
| Female | 153.5 ± 30.0 | 99.14 ± 14.0 | 246.9 ± 14.6 | 1.92 ± 0.05 | 1.03 ± 0.07 | 9.82 ± 0.60 | 2.38 ± 0.16 | 0.69 ± 0.07 | 1.75 ± 0.20 | |
| BC | Male | 158.8 ± 17.1 | 144.7 ± 13.4 | 309.7 ± 6.7 | 1.77 ± 0.25 | 1.12 ± 0.06 | 11.06 ± 0.55 | 2.20 ± 0.16 | 0.82 ± 0.08 | 1.68 ± 0.09 |
| Female | 176.9 ± 40.3 | 109.7 ± 24.2 | 258.2 ± 5.1 | 1.92 ± 0.13 | 1.00 ± 0.08 | 9.14 ± 0.79 | 2.34 ± 0.20 | 0.85 ± 0.06 | 1.77 ± 0.19 | |
| CSS | Male | 167.9 ± 30.0 | 141.7 ± 13.8 | 314.2 ± 18.4 | 1.83 ± 0.18 | 1.18 ± 0.15 | 11.82 ± 0.81 | 2.41 ± 0.23 | 0.94 ± 0.04 | 1.81 ± 0.15 |
| Female | 192.5 ± 33.5 | 122.1 ± 25.6 | 251.3 ± 10.8 | 1.82 ± 0.11 | 0.93 ± 0.12 | 9.43 ± 0.70 | 2.14 ± 0.13 | 0.73 ± 0.14 | 1.73 ± 0.10 | |
| BCCSS | Male | 162.9 ± 19.1 | 136.5 ± 18.5 | 318.9 ± 11.9 | 1.88 ± 0.35 | 1.11 ± 0.12 | 11.08 ± 0.56 | 2.37 ± 0.09 | 0.85 ± 0.07 | 1.76 ± 0.07 |
| Female | 197.3 ± 44.5 | 116.6 ± 20.4 | 238.9 ± 5.2 | 1.73 ± 0.24 | 0.91 ± 0.06 | 8.25 ± 0.42 | 2.12 ± 0.27 | 0.68 ± 0.12 | 1.70 ± 0.12 | |
The data represent the mean ± standard deviation. p < 0.05.
Assessment of the biochemical parameters of male and female rats after exposure to BC, CSS and BCCSS for 30 days.
| Biochemical parameters | Animals | Negative control | BC | CSS | BCCSS |
|---|---|---|---|---|---|
| Urea (mg/dL) | Male | 33.45 ± 3.96 | 38.14 ± 4.28 | 38.49 ± 3.24 | 26.70 ± 3.56 |
| Female | 42.80 ± 8.70 | 38.92 ± 9.00 | 22.06 ± 2.2 | 26.10 ± 5.20 | |
| Creatinine (mg/dL) | Male | 0.20 ± 0.07 | 0.28 ± 0.10 | 0.20 ± 0.08 | 0.31 ± 0.09 |
| Female | 0.38 ± 0.10 | 0.32 ± 0.13 | 0.22 ± 0.04 | 0.22 ± 0.10 | |
| AST (U/L) | Male | 79.38 ± 34.71 | 120.3 ± 21.82 | 85.80 ± 20.13 | 76.57 ± 20.13 |
| Female | 67.67 ± 18.5 | 90.22 ± 28.9 | 64.55 ± 23.4 | 62.42 ± 28.60 | |
| ALT (U/L) | Male | 25.57 ± 5.70 | 36.41 ± 4.70 | 31.26 ± 6.9 | 29.39 ± 5.30 |
| Female | 40.14 ± 5.24 | 47.78 ± 14.70 | 27.93 ± 7.64 | 37.92 ± 8.16 | |
| Bilirubin (mg/dL) | Male | 0.05 ± 0.01 | 0.07 ± 0.01 | 0.07 ± 0.01 | 0.07 ± 0.01 |
| Female | 0.19 ± 0.05 | 0.15 ± 0.02 | 0.10 ± 0.03* | 0.08 ± 0.03* | |
| AF (mU/mL) | Male | 132.4 ± 10.21 | 234.0 ± 67.87 | 160.6 ± 26.78 | 207.6 ± 85.80 |
| Female | 316.6 ± 19.02 | 244.9 ± 61.75 | 109.0 ± 14.8* | 211.8 ± 59.50* | |
The data represent the mean ± standard deviation. p < 0.05; *p < 0.01.AST—aspartate aminotransferase; ALT—alanine aminotransferase; AF—alkaline phosphatase.
Differential count and evaluation of leukocytes of the male and female rats submitted to 30 days of exposure to BC, CSS and BCCSS.
| Animals | Negative Control | BC | CSS | BCCSS | |
|---|---|---|---|---|---|
| Leukocytes (103/mm3) | Male | 3.60 ± 0.9 | 5.86 ± 2.1 | 8.75 ± 1.1* | 6.76 ± 1.3* |
| Female | 5.08 ± 0.6 | 5.20 ± 1.2 | 3.32 ± 0.6* | 3.37 ± 0.7* | |
| Targeted (%) | Male | 21.46 ± 8.3 | 28.1 ± 3.7 | 24.00 ± 4.2 | 22.58 ± 5.6 |
| Female | 23.25 ± 2.1 | 20.61 ± 4.8 | 19.25 ± 4.1 | 17.62 ± 3.9 | |
| Rods (%) | Male | 1.30 ± 0.7 | 1.60 ± 0.8 | 1.20 ± 0.3 | 2.25 ± 1.3 |
| Female | 0.58 ± 0.5 | 0.53 ± 0.5 | 0.75 ± 0.4 | 0.75 ± 0.4 | |
| Eosinophils (%) | Male | 0.69 ± 0.6 | 0.70 ± 0.5 | 1.10 ± 0.2 | 0.66 ± 0.7 |
| Female | 0.50 ± 0.5 | 0.38 ± 0.4 | 0.75 ± 0.7 | – | |
| Lymphocytes (%) | Male | 68.92 ± 8.2 | 65.7 ± 4.0 | 71.20 ± 4.5 | 79.75 ± 4.7* |
| Female | 70.08 ± 4.1 | 75.92 ± 5.2 | 76.83 ± 5.5 | – | |
| Monocytes (%) | Male | 3.76 ± 1.6 | 3.90 ± 1.1 | 2.70 ± 1.4 | 3.33 ± 1.8 |
| Female | 5.58 ± 3.7 | 2.53 ± 1.3 | 2.41 ± 1.4 | 1.87 ± 0,9 | |
| Basophils (%) | Male | – | – | – | – |
| Female | – | – | – | – | |
The data represent the mean ± standard deviation. p < 0.05; *p < 0.01.
Assessment of the red blood cells of male and female rats after exposure to BC, CSS and BCCSS for 30 days.
| Animals | Negative Control | BC | CSS | BCCSS | |
|---|---|---|---|---|---|
| RCB (106/mm3) | Male | 4.22 ± 1.0 | 4.343 ± 0.8 | 4.742 ± 0.4 | 4.19 ± 1.2 |
| Female | 7.58 ± 0.2 | 7.32 ± 0.3 | 7.70 ± 0.3 | 7.77 ± 0.4 | |
| Hemoglobin (g/dL) | Male | 7.68 ± 1.7 | 8.050 ± 1.5 | 8.860 ± 0.8 | 8.58 ± 0.8 |
| Female | 14.27 ± 0.3 | 13.93 ± 0.5 | 14.70 ± 0.7 | 14.16 ± 0.8 | |
| Hematocrit (%) | Male | 21.63 ± 5.4 | 22.78 ± 4.4 | 24.46 ± 2.3 | 23.86 ± 2.5 |
| Female | 42.45 ± 1.3 | 41.50 ± 1.5 | 43.16 ± 2.1 | 42.00 ± 2.2 | |
| MCV (m3) | Male | 51.14 ± 1.5 | 52.33 ± 1.9 | 51.40 ± 0.9 | 51.00 ± 1.5 |
| Female | 56.00 ± 1.5 | 56.67 ± 2.0 | 56.14 ± 1.3 | 53.90 ± 1.1 | |
| MCH (g.10−12) | Male | 18.21 ± 0.9 | 18.52 ± 0.4 | 18.64 ± 0.2 | 18.52 ± 0.2 |
| Female | 18.72 ± 0.4 | 19.00 ± 0.7 | 19.10 ± 0.6 | 18.20 ± 0.4 | |
| MCHC (g/dL) | Male | 35.70 ± 1.6 | 35.42 ± 0.7 | 36.16 ± 0.2 | 36.25 ± 0.9 |
| Female | 33.67 ± 0.8 | 33.58 ± 0.1 | 34.06 ± 0.8 | 33.72 ± 0.6 | |
| RDW (%) | Male | 13.59 ± 0.6 | 14.37 ± 1.2 | 13.34 ± 0.3 | 13.57 ± 0.7 |
| Female | 14.78 ± 0.4 | 14.23 ± 0.8 | 14.60 ± 0.5 | 14.02 ± 0.7 | |
The data represent the mean ± standard deviation p < 0.05. RBC—red blood cells; MCV— mean corpuscular volume; MCH—mean corpuscular hemoglobin; MCHC—mean corpuscular hemoglobin concentration; RDW—red cell distribution width.
Fig. 3Cortical region of the kidneys of male Wistar rats submitted to 30 days of exposure A—kidney of the control group; B—kidney of the BCCSS group (male rat); C—kidney of the BCCSS group (female rat). *yellow arrow—amorphous eosinophilic material.